ProfileGDS5678 / 1449120_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 73% 72% 72% 74% 75% 75% 73% 72% 72% 73% 73% 75% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9518475
GSM967853U87-EV human glioblastoma xenograft - Control 24.6683173
GSM967854U87-EV human glioblastoma xenograft - Control 34.6434172
GSM967855U87-EV human glioblastoma xenograft - Control 44.7137472
GSM967856U87-EV human glioblastoma xenograft - Control 54.8823774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8900875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8518875
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.731573
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6497572
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5849872
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6870173
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7678473
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9615475
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.719473